Alofanib (RPT835) is primarily investigated for its potential in cancer treatment, particularly as an inhibitor of fibroblast growth factor receptors (FGFRs). FGFRs play a significant role in cell proliferation, survival, and differentiation, and their dysregulation is often associated with various cancers. By targeting these receptors, Alofanib aims to disrupt the signaling pathways that promote tumor growth and progression. It is being studied for its efficacy in treating solid tumors, including those resistant to conventional therapies. Additionally, its potential to inhibit angiogenesis, the process by which tumors develop new blood vessels, makes it a promising candidate for reducing tumor metastasis and improving patient outcomes in advanced cancer stages. Research is ongoing to explore its therapeutic benefits and safety profile in clinical settings.